EcoDrugPlus

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSHCOG00000013139
Gene Symbol: LOC109518868
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSHCOG00000019271
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSHCOG00000018981
Gene Symbol: CXCR4
4 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSHCOG00000007359
Gene Symbol: LOC109529008
2 Cross references
350 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSHCOG00000007372
Gene Symbol: LOC109529006
2 Cross references
350 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSHCOG00000007368
Gene Symbol: LOC109529007
2 Cross references
350 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSHCOG00000015934
Gene Symbol: CFTR
3 Cross references
193 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSHCOG00000003799
Gene Symbol: LOC109512440
3 Cross references
198 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSHCOG00000006382
Gene Symbol: LOC109514277
3 Cross references
181 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSHCOG00000016624
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSHCOG00000003669
Gene Symbol: LOC109521497
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSHCOG00000017846
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).